Table 1.
Methods and basis for reclassification of 28 parotid gland carcinomas
| Patient no | Primary diagnosis | Revised diagnosis | Methods and basis for reclassification | |
|---|---|---|---|---|
| 1 | MEC | MASC HG | FISH | Translocation ETV6-NTRK3 |
| 2 | ACa NOS | MASC HG | FISH | Translocation ETV6-NTRK3 |
| 3 | ACa NOS | MASC LG | FISH | Translocation ETV6-NTRK3 |
| 4 | AcCC | MASC LG | FISH | Translocation ETV6-NTRK3 |
| 5 | AcCC | MASC LG | FISH | Translocation ETV6-NTRK3 |
| 6 | Papillary CAC | MASC LG | FISH | Translocation ETV6-NTRK3 |
| 7 | UCa | NCa | IHC | Chromogranin+, CD56+, synaptophysin+, TTF1−, S100−, CK20−, CK7− |
| 8 | SCC G2 | SDC | IHC | AR−, HER2+, CK7+, p63−, S100− |
| 9 | CxPA | SDC | IHC | AR+ (20 %), HER2+, CK7+ |
| 10 | MEC HG | SDC | IHC | AR+, HER2+, CK7+, p63−, S100−, EMA+ |
| 11 | MEC HG | SDC | IHC | AR−, HER2+, CK7+, p63−, S100−, EMA+ |
| 12 | ACa NOS | AcCC | IHC | CK8+, CK7−, PAS+, DOG1+ |
| 13 | AdCC | AcCC | IHC | DOG1+, PAS+ |
| 14 | MEC | EMCa LG | IHC | P63+, CK7+, CK14+, calponin focally+ |
| 15 | BCAca | EMCa LG | IHC | P63+, CK7+, CK14+, calponin+ |
| 16 | AcCC | EMCa LG | IHC | P63+, CK7+, CK14+, calponin+ |
| 17 | CxPA (SDC) | CXPA in situ | H&E | |
| 18 | CxPA (ACa NOS) | CXPA in situ | H&E | |
| 19 | CxPA | PA with SCM | H&E | Lack of atypia |
| 20 | MEC | PA with SCM | H&E/FISH | Lack of translocation CTRC1-MAML2/CTRC3-MAML2 |
| 21 | Clear cell Ca | Myoepithelioma (clear cell variant) | IHC | S100+, SMA+, calponin+, GFAP+ |
| 22 | MEC | Metaplastic WT | H&E/FISH | Lack of translocation CTRC1-MAML2/CTRC3-MAML2 |
| 23 | PLGA | Necrotizing sialometaplasia | H&E | |
| 24 | MEC | SCC metastases (skin) | H&E/clinical data/follow-up | PAS−, mucicarmine− |
| 25 | Clear cell Ca | RCC metastases | IHC/clinical data/follow-up | CD10+, RCC+ |
| 26 | AcCC | RCC metastases | IHC/clinical data/follow-up | CD10+, RCC+ |
| 27 | AcCC | RCC metastases | IHC/clinical data/follow-up | CD10+, RCC+ |
| 28 | AcCC | BC metastases | IHC/clinical data/follow-up | Mammaglobin + |
MASC mammary analogue secretory carcinoma, SDC salivary duct carcinoma, ACA NOS adenocarcinoma not otherwise specified, CxPA carcinoma ex pleomorphic adenoma, MEC mucoepidermoid carcinoma, SCC squamous cell carcinoma, AcCC acinic cell carcinoma, AdCC adenoid cystic carcinoma, EMCa epithelial–myoepithelial carcinoma, UCa undifferentiated carcinoma, PLGA polymorphous low-grade adenocarcinoma, NCa neuroendocrine carcinoma, CAC cystadenocarcinoma, RCC renal cell carcinoma, BC breast carcinoma, WT Warthin tumour, PA pleomorphic adenoma, SCM squamous cell metaplasia, HG high grade, IG intermediate grade, LG low grade, H&E hematoxylin and eosin, IHC immunohistochemistry